Plasminogen activator pathway (PA pathway)

The Plasminogen activator pathway is a complex enzymatic system responsible for the conversion of the inactive proenzyme plasminogen into plasmin, the primary enzyme involved in fibrin degradation, a process known as fibrinolysis [StatPearls: NBK546610]. This system is driven by two principal activators: tissue-type plasminogen activator (tPA), which primarily mediates intravascular thrombolysis, and urokinase-type plasminogen activator (uPA), which facilitates cell migration and tissue remodeling by binding to the uPA receptor (uPAR) [UniProt: P00750, P00749]. The pathway is tightly regulated by specific inhibitors, most notably plasminogen activator inhibitor-1 (PAI-1) and PAI-2, which prevent excessive proteolytic activity and maintain hemostatic balance [UniProt: P05121]. In clinical practice, this pathway is a major therapeutic target for treating acute myocardial infarction and ischemic stroke through the administration of recombinant tPA analogs like alteplase [PubMed: 11511412]. Conversely, antifibrinolytic drugs such as tranexamic acid are used to stabilize clots and reduce bleeding by inhibiting plasminogen activation [PubMed: 22991244]. Beyond its role in hemostasis, the pathway is heavily implicated in cancer progression, where uPA-mediated matrix degradation promotes tumor invasion and metastasis [PubMed: 12873821]. Dysregulation of this pathway is also associated with inflammatory conditions and impaired wound healing [PubMed: 10666472].

Other names

Plasminogen activator systemFibrinolytic systemuPA/tPA systemPlasminogen-plasmin system

Drugs targeting this pathway either act as plasminogen activators to promote fibrinolysis by converting plasminogen to plasmin, or as antifibrinolytics that inhibit plasminogen activation or plasmin activity to prevent clot degradation.